Profile Detail

Chester Mathis, PhD

UPMC Endowed Chair of PET Research and Distinguished Professor of Radiology

Interest (in 3 to 10 words):

Education University of California, Davis, PhD in Chemistry, 1979
B.S. Chemistry, Humboldt State University, Arcata, CA
Medical / Graduate School PhD, Physical Chemistry, University of California, Davis
Clinical / Post-doctoral Fellowship Radiochemistry, University of California, Davis
Radiochemistry, University of California, Berkeley
Current Academy of Molecular Imaging
American Association for the Advancement of Science
American Chemical Society (Division of Fluorine Chemistry; Division of Medicinal
Chemistry; Division of Nuclear Science and Technology)
Society for Neuroscience
Society of Nuclear Medicine (Brain Imaging Council; Radiopharmaceutical Science Council)
Society of Radiopharmaceutical Chemistry and Biology
& Programs
Nuclear Medicine
Clinical Interest
Research Interest Development of radiopharmaceuticals for PET imaging in neuroscience and oncology applications

Selected Publications   Mathis CA, Wang Y, Holt DP, Huang G-F, Debnath ML, Klunk WE. Synthesis and Evaluation of 11C-Labeled 6-Substituted 2-Aryl Benzothiazoles as Amyloid Imaging Agents. J Med Chem 46:2740-55 (2003).

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Huang G-F, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B. Imaging Brain Amyloid in Alzheimer's Disease with Pittsburgh Compound-B. Annals of Neurology 55:306-19 (2004).

Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Paljug WR, Debnath ML, Isanski BA, Hamilton RL and DeKosky ST. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131:1630-1645.

Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Snitz B, Houck P, Bi W, Cohen A, Lopresti BJ, DeKosky ST, Halligan E, Klunk WE. Amyloid deposition is frequent and often is not associated with significant cognitive impairment in the elderly. Arch Neurol 2008; 65:1509-17.

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, de Liano SR, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. (11)C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9:363-72

Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC. Longitudinal assessment of A and cognition in aging and Alzheimer disease. Annals of Neurology 2011; 69:181-92.

Frankle WG, Cho RY, Narendran R, Mason NS, Vora S, Litschge M, Price JC, Lewis DA, Mathis CA. Tiagabine Increases [11C]Flumazenil Binding in Cortical Brain Regions in Healthy Control Subjects. Neuropsychopharmacology 2009; 34:624-33.

Frankle WG, Mason NS, Rabiner EA, Ridler K, May MA, Asmonga D, Chen CM, Kendro S, Cooper TB, Mathis CA, Narendran R. No effect of dopamine depletion on the binding of the high affinity D(2/3) radiotracer [(11)C]FLB 457 in the human cortex. Synapse 2010; 64:879-85.

Narendran R, Mason NS, May MA, Chen CM, Kendro S, Ridler K, Rabiner EA, Laruelle M, Mathis CA, Frankle WG. PET imaging of dopamine D(2/3) receptors in the human cortex with [(11)C]FLB 457: Reproducibility studies. Synapse 2011; 65:35-40.
Honors and  
Distinguished Alumni Award, Humboldt State University, April 2012

Distinguished Professor of Radiology, University of Pittsburgh, February 2012
PubMed Publications   See a listing of publications on PubMed, a service of the National Library of medicine.